Get started
Author

Kiran R. Vij

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
2017 · Cynthia X. Ma, Feng Gao, et al. · Clinical Cancer Research · 366
Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis
2004 · Sanjay Jain, Cathy K. Naughton, et al. · Development · 124
NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health
2022 · Writing Group, Patty J. Lee, et al. · Nature Aging · 122
PDF
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity
2023 · Xiuting Liu, Graham D. Hogg, et al. · Cancer Cell · 99
PDF
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease
2018 · Jaebok Choi, Matthew L. Cooper, et al. · Leukemia · 90
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
2017 · Nusayba Bagegni, Shana Thomas, et al. · Breast Cancer Research · 73
PDF
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer
2017 · Cynthia X. Ma, Vera Suman, et al. · Clinical Cancer Research · 73
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
2020 · Cynthia X. Ma, Vera J. Suman, et al. · Journal of Clinical Oncology · 44
Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo
2017 · Matthew L Cooper, Jaebok Choi, et al. · The Journal of Immunology · 43
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
2019 · Scott R. Goldsmith, Sana Saif Ur Rehman, et al. · Blood Advances · 41
PDF
Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer
2020 · Cuige Zhu, Anna Rogers, et al. · Cell Reports · 33
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
2024 · Cynthia X. Ma, Vera J. Suman, et al. · JAMA Oncology · 27
PDF
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
2024 · James R. Cerhan, Matthew J. Maurer, et al. · American Journal of Hematology · 27
PDF
Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis
2019 · Mina L. Xu, Ali Gabali, et al. · The American Journal of Surgical Pathology · 25
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR
2021 · Sena Kim, Kidist Ashami, et al. · Leukemia · 24
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
2022 · Erica K. Barnell, Zachary L. Skidmore, et al. · Blood Advances · 20
PDF
HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice
2017 · Alison K. Esser, Daniel A. Rauch, et al. · Oncotarget · 19
PDF
Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)
2016 · CX Ma, F Gao, et al. · Cancer Research · 15
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
2024 · Naomi Yamamoto, Stephanie Dobersch, et al. · Clinical Cancer Research · 12
Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications
2023 · Arushi Khurana, Raphael Mwangi, et al. · Blood · 9
Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
2021 · Cynthia X Ma, Vera Suman, et al. · Cancer Research · 9
Selective targeting of α4β1 integrin attenuates murine graft versus host disease
2020 · Bader Alahmari, Matthew L. Cooper, et al. · Leukemia · 9
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 · Christopher R Flowers, Brian K. Link, et al. · Blood · 8
Aberrant Expression of α-Fetoprotein in Intrahepatic Cholangiocarcinoma: An Exceptional Occurrence
2008 · Kiran Vij, Hanlin L. Wang · International Journal of Surgical Pathology · 8
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
2024 · Brooj Abro, Matthew J. Maurer, et al. · Blood · 7
PDF
Works count: 121
Citation count: 1,387
H-index: 17
I10-index: 19
Year
Topic
Type